Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Journal
Document Type
Year range
1.
Cutis ; 109(3): 148-149, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1870121

ABSTRACT

The devastating effects of the COVID-19 pandemic have prompted rapid development and distribution of multiple vaccines. A 2-dose messenger RNA (mRNA) vaccine developed by Moderna (Moderna COVID-19 Vaccine) was approved in December 2020 for the prevention of COVID-19. We describe a case of BCG vaccination scar reactivation in a 48-year-old man after he received the first dose of the Moderna COVID-19 Vaccine.


Subject(s)
2019-nCoV Vaccine mRNA-1273 , COVID-19 , Cicatrix , 2019-nCoV Vaccine mRNA-1273/adverse effects , BCG Vaccine , COVID-19/prevention & control , Cicatrix/etiology , Humans , Male , Middle Aged , Pandemics , Vaccination/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL